Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Aspirin, metformin and statins: Promising targeted adjuncts in rectal cancer

11 Aug 2017

Aspirin, metformin and statins demonstrate utility as adjuncts to neoadjuvant treatment in rectal cancer, resulting in increased downstaging of rectal tumours, according to a recent study.

Researchers performed a systematic literature search of studies investigating the use of drugs to enhance response to neoadjuvant radiation in rectal cancer. Of the 2,137 studies identified, only nine studies were included in the final review. A narrative review was conducted due to the limited number of randomized controlled trials and the heterogeneity of relevant trials.

Results showed that the use of statins or aspirin during neoadjuvant therapy led to a significantly higher rate of tumour downstaging. Statins particularly emerged as a significant predictor of complete tumour response, whereas aspirin was associated with a greater 5-year progression-free survival and overall survival.

Meanwhile, metformin use was associated with a significantly higher overall and disease-free survival, especially in a subset of rectal cancer patients with diabetes.

The results highlight a clear need for prospective randomized controlled trials to determine the true impact of statins, aspirin and metformin as adjuncts, singularly or in combination, and whether they confer an increase in response to neoadjuvant therapy or a long-term effect on survival, researchers said.

In rectal cancer, complete tumour response to neoadjuvant chemoradiotherapy has been reported to reduce the risk of local recurrence and improve disease-free and overall survival. However, such response is achieved in only 20 to 30 percent of patients. [Dis Colon Rectum 2015;58:32–44; J Clin Oncol 2009;27:5124–5130; Surg Oncol Clin N Am 2010;19:829–845]

Optimizing response to treatment is now fundamental to improving outcomes from rectal cancer, in both early and locally advanced stages, especially because malignancies (as they develop) acquire both epigenetic and genetic changes that promote therapy resistance and evasion of apoptosis—an important hallmark of cancer. [Br J Surg 2014;101:1299–1309; Cell 2011;144:646–674]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Roshini Claire Anthony, 05 Jan 2018

The addition of daratumumab to a bortezomib-melphalan-prednisone (VMP) regimen appears to improve progression-free survival (PFS) over VMP alone in individuals newly diagnosed with multiple myeloma who are ineligible for stem-cell transplantation, according to findings from the phase III ALCYONE* trial.

01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.